精神分裂症

American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., (DSM-5). Washington, DC: American Psychiatric Publishing; 2013.

National Institute for Health and Care Excellence. Psychosis and schizophrenia in children and young people: recognition and management. Oct 2016 [internet publication].全文

Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012 Jul;13(5):318-78.全文  摘要

Correll CU, Rubio JM, Inczedy-Farkas G, et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry. 2017 Jul 1;74(7):675-84.全文  摘要

Fusar-Poli P, Kempton MJ, Rosenheck RA. Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin Psychopharmacol. 2013 Mar;28(2):57-66. 摘要

Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005 Sep 22;353(12):1209-23.全文  摘要

Canadian Agency for Drugs and Technologies in Health. Group therapy in the treatment of schizophrenia: a review of the clinical effectiveness. Nov 2009 [internet publication].全文

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., (DSM-5). Washington, DC: American Psychiatric Publishing; 2013.

2. McGrath J, Saha S, Chant D, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008 Nov 1;30(1):67-76.全文  摘要

3. McGrath JJ. Myths and plain truths about schizophrenia epidemiology - the NAPE lecture 2004. Acta Psychiatr Scand. 2005 Jan;111(1):4-11. 摘要

4. Jablensky A, Sartorius N, Ernberg G, et al. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monogr Suppl. 1992;20:1-97. 摘要

5. Gupta S, Murray RM. The relationship of environmental temperature to the incidence and outcome of schizophrenia. Br J Psychiatry. 1992 Jun;160:788-92. 摘要

6. Piotrowski P, Gondek TM, Królicka-Deręgowska A, et al. Causes of mortality in schizophrenia: an updated review of European studies. Psychiatr Danub. 2017 Jun;29(2):108-20.全文  摘要

7. Mitchell AJ, Malone D. Physical health and schizophrenia. Curr Opin Psychiatry. 2006 Jul;19(4):432-7. 摘要

8. Fazel S, Wolf A, Palm C, et al. Violent crime, suicide, and premature mortality in patients with schizophrenia and related disorders: a 38-year total population study in Sweden. Lancet Psychiatry. 2014 Jun;1(1):44-54.全文  摘要

9. Torrey EF, Miller J, Rawlings R, et al. Seasonal birth patterns of neurological disorders. Neuroepidemiology. 2000 Jul-Aug;19(4):177-85. 摘要

10. McGrath JJ, Welham JL. Season of birth and schizophrenia: a systematic review and meta-analysis of data from the Southern Hemisphere. Schizophr Res. 1999 Feb 15;35(3):237-42. 摘要

11. Bota RG, Munro JS, Sagduyu K. Identification of the schizophrenia prodrome in a hospital-based patient population. Mo Med. 2005 Mar-Apr;102(2):142-6. 摘要

12. Werbeloff N, Levine SZ, Rabinowitz J. Elaboration on the association between immigration and schizophrenia: a population-based national study disaggregating annual trends, country of origin and sex over 15 years. Soc Psychiatry Psychiatr Epidemiol. 2012 Feb;47(2):303-11. 摘要

13. Bourque F, van der Ven E, Malla A. A meta-analysis of the risk for psychotic disorders among first- and second-generation immigrants. Psychol Med. 2011 May;41(5):897-910. 摘要

14. National Institute for Health and Care Excellence. Psychosis and schizophrenia in children and young people: recognition and management. Oct 2016 [internet publication].全文

15. Walker EF, Diforio D. Schizophrenia: a neural diathesis-stress model. Psychol Rev. 1997 Oct;104(4):667-85. 摘要

16. Tsuang M. Schizophrenia: genes and environment. Biol Psychiatry. 2000 Feb 1;47(3):210-20. 摘要

17. Hough CJ, Ursano RJ. A guide to the genetics of psychiatric disease. Psychiatry. 2006 Spring;69(1):1-20. 摘要

18. Kuswanto CN, Teh I, Lee T-S, et al. Diffusion tensor imaging findings of white matter changes in first episode schizophrenia: a systematic review. Clin Psychopharmacol Neurosci. 2012 Apr;10(1):13-24.全文  摘要

19. Huber G. Prodromal symptoms in schizophrenia [in German]. Fortschr Neurol Psychiatr. 1995 Apr;63(4):131-8. 摘要

20. McCarley RW, Wible CG, Frumin M, et al. MRI anatomy of schizophrenia. Biol Psychiatry. 1999 May 1;45(9):1099-119.全文  摘要

21. Andreasen NC, Rezai K, Alliger R, et al. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry. 1992 Dec;49(12):943-58. 摘要

22. Keshavan MS, Reynolds CF, Miewald MJ, et al. Delta sleep deficits in schizophrenia: evidence from automated analyses of sleep data. Arch Gen Psychiatry. 1998 May;55(5):443-8.全文  摘要

23. Salisbury DF, Shenton ME, McCarley RW. P300 topography differs in schizophrenia and manic psychosis. Biol Psychiatry. 1999 Jan 1;45(1):98-106. 摘要

24. Light GA, Geyer MA, Clementz BA, et al. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am J Psychiatry. 2000 May;157(5):767-71. 摘要

25. Sawa A, Snyder SH. Schizophrenia: diverse approaches to a complex disease. Science. 2002 Apr 26;296(5568):692-5. 摘要

26. Laruelle M. Imaging dopamine transmission in schizophrenia: a review and meta-analysis. Q J Nucl Med. 1998 Sep;42(3):211-21. 摘要

27. Laruelle M, Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol. 1999 Dec;13(4):358-71. 摘要

28. Schobel SA, Chaudhury NH, Khan UA, et al. Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron. 2013 Apr 10;78(1):81-93.全文  摘要

29. Smith TE, Hull JW, Huppert JD, et al. Insight and recovery from psychosis in chronic schizophrenia and schizoaffective disorder patients. J Psychiatr Res. 2004 Mar-Apr;38(2):169-76. 摘要

30. Miller B, Messias E, Miettunen J, et al. Meta-analysis of paternal age and schizophrenia risk in male versus female offspring. Schizophr Bull. 2011 Sep;37(5):1039-47.全文  摘要

31. Clarke MC, Harley M, Cannon M. The role of obstetric events in schizophrenia. Schizophr Bull. 2006 Jan;32(1):3-8.全文  摘要

32. Macleod J, Davey Smith G, Hickman M. Does cannabis use cause schizophrenia? Lancet. 2006 Apr 1;367(9516):1055. 摘要

33. Arseneault L, Cannon M, Witton J, et al. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry. 2004 Feb;184:110-7. 摘要

34. Arendt M, Rosenberg R, Foldager L, et al. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Br J Psychiatry. 2005 Dec;187:510-5. 摘要

35. Kuepper R, van Os J, Lieb R, et al. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ. 2011 Mar 1;342:d738.全文  摘要

36. McGrath J, Welham J, Scott J, et al. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch Gen Psychiatry. 2010 May;67(5):440-7.全文  摘要

37. Hjorthøj C, Albert N, Nordentoft M. Association of substance use disorders with conversion from schizotypal disorder to schizophrenia. JAMA Psychiatry. 2018 Jul 1;75(7):733-9.全文  摘要

38. Schoeler T, Petros N, Di Forti M, et al. Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis. Lancet Psychiatry. 2017 Aug;4(8):627-33.全文  摘要

39. Ziermans T, de Wit S, Schothorst P, et al. Neurocognitive and clinical predictors of long-term outcome in adolescents at ultra-high risk for psychosis: a 6-year follow-up. PLoS One. 2014 Apr 4;9(4):e93994.全文  摘要

40. Mittal VA, Dean DJ, Bernard JA, et al. Neurological soft signs predict abnormal cerebellar-thalamic tract development and negative symptoms in adolescents at high risk for psychosis: a longitudinal perspective. Schizophr Bull. 2014 Nov;40(6):1204-15.全文  摘要

41. Dean DJ, Bernard JA, Orr JM, et al. Cerebellar morphology and procedural learning impairment in neuroleptic-naive youth at ultrahigh risk of psychosis. Clin Psychol Sci. 2014 Mar;2(2):152-64.全文  摘要

42. Bernard JA, Dean DJ, Kent JS, et al. Cerebellar networks in individuals at ultra high-risk of psychosis: impact on postural sway and symptom severity. Hum Brain Mapp. 2014 Aug;35(8):4064-78.全文  摘要

43. Corcoran C, Walker E, Huot R, et al. The stress cascade and schizophrenia: etiology and onset. Schizophr Bull. 2003;29(4):671-92. 摘要

44. Morgan C, Fisher H. Environment and schizophrenia: environmental factors in schizophrenia: childhood trauma - a critical review. Schizophr Bull. 2007 Jan;33(1):3-10.全文  摘要

45. Bradbury TN, Miller GA. Season of birth in schizophrenia: a review of evidence, methodology, and etiology. Psychol Bull. 1985 Nov;98(3):569-94. 摘要

46. Norman RM, Malla AK. Duration of untreated psychosis: a critical examination of the concept and its importance. Psychol Med. 2001 Apr;31(3):381-400. 摘要

47. McGlashan TH. Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course? Biol Psychiatry. 1999 Oct 1;46(7):899-907. 摘要

48. Harrigan SM, McGorry PD, Krstev H. Does treatment delay in first-episode psychosis really matter? Psychol Med. 2003 Jan;33(1):97-110. 摘要

49. Craig TJ, Bromet EJ, Fennig S, et al. Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series? Am J Psychiatry. 2000;157:60-66. 摘要

50. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999 Mar;56(3):241-7. 摘要

51. Marshall M, Rathbone J. Early intervention for psychosis. Cochrane Database Syst Rev. 2011 Jun 15;(6):CD004718.全文  摘要

52. Correll CU, Galling B, Pawar A, et al. Comparison of early intervention services vs treatment as usual for early-phase psychosis: a systematic review, meta-analysis, and meta-regression. JAMA Psychiatry. 2018 Jun 1;75(6):555-65.全文  摘要

53. Tsuang MT, Stone WS, Faraone SV. Understanding predisposition to schizophrenia: toward intervention and prevention. Can J Psychiatry. 2002 Aug;47(6):518-26. 摘要

54. Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull. 1996;22(2):353-70. 摘要

55. Klosterkötter J, Ebel H, Schultze-Lutter F, et al. Diagnostic validity of basic symptoms. Eur Arch Psychiatry Clin Neurosci. 1996;246(3):147-54. 摘要

56. Klosterkötter J, Hellmich M, Steinmeyer EM, et al. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry. 2001 Feb;58(2):158-64.全文  摘要

57. Yung AR, Phillips LJ, McGorry PD, et al. Prediction of psychosis: a step towards indicated prevention of schizophrenia. Br J Psychiatry Suppl. 1998;172(33):14-20. 摘要

58. Yung AR, Phillips LJ, Yuen HP, et al. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr Res. 2003 Mar 1;60(1):21-32. 摘要

59. Miller TJ, McGlashan TH, Rosen JL, et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry. 2002 May;159(5):863-5. 摘要

60. Rector NA, Beck AT, Stolar N. The negative symptoms of schizophrenia: a cognitive perspective. Can J Psychiatry. 2005 Apr;50(5):247-57. 摘要

61. Chapman CL, Mullin K, Ryan CJ. Meta-analysis of the association between suicidal ideation and later suicide among patients with either a schizophrenia spectrum psychosis or a mood disorder. Acta Psychiatr Scand. 2015 Mar;131(3):162-73. 摘要

62. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005 Mar;62(3):247-53.全文  摘要

63. Hawton K, Sutton L, Haw C, et al. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry. 2005 Jul;187:9-20. 摘要

64. Hor K, Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol. 2010 Nov;24(4 suppl):81-90.全文  摘要

65. Dazzan P, Murray RM. Neurological soft signs in first-episode psychosis: a systematic review. Br J Psychiatry Suppl. 2002 Sep;43:s50-7. 摘要

66. Tosato S, Dazzan P. The psychopathology of schizophrenia and the presence of neurological soft signs: a review. Curr Opin Psychiatry. 2005 May;18(3):285-8. 摘要

67. Rossi A, De Cataldo S, Di Michele V, et al. Neurological soft signs in schizophrenia. Br J Psychiatry. 1990 Nov;157:735-9. 摘要

68. Venkatasubramanian G, Latha V, Gangadhar BN, et al. Neurological soft signs in never-treated schizophrenia. Acta Psychiatr Scand. 2003 Aug;108(2):144-6. 摘要

69. World Health Organization. International statistical classification of diseases and related health problems, 11th revision (ICD-11). Chapter 6: mental, behavioural or neurodevelopmental disorders. 2018 [internet publication].全文

70. Bradizza CM, Stasiewicz PR. Integrating substance abuse treatment for the seriously mentally ill into inpatient psychiatric treatment. J Subst Abuse Treat. 1997 Mar-Apr;14(2):103-11. 摘要

71. Ebel H, Schlegel U, Klosterkötter J. Chronic schizophreniform psychosis in primary hyperparathyroidism [in German]. Nervenarzt. 1992 Mar;63(3):180-3. 摘要

72. Engelhardt. Psychosis in primary hyperparathyroidism [in German]. Internist (Berl). 1991 Dec;32(12):738. 摘要

73. Joborn C, Hetta J, Palmér M, et al. Psychiatric symptomatology in patients with primary hyperparathyroidism. Ups J Med Sci. 1986;91(1):77-87. 摘要

74. Amador XF, Flaum M, Andreasen NC, et al. Awareness of illness in schizophrenia and schizoaffective and mood disorders. Arch Gen Psychiatry. 1994 Oct;51(10):826-36. 摘要

75. Hjorthøj C, Stürup AE, McGrath JJ, et al. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017 Apr;4(4):295-301. 摘要

76. Vermeulen J, van Rooijen G, Doedens P, et al. Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis. Psychol Med. 2017 Oct;47(13):2217-28. 摘要

77. Bola JR, Kao DT, Soydan H. Antipsychotic medication for early-episode schizophrenia. Schizophr Bull. 2012 Jan;38(1):23-5.全文  摘要

78. Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD000076. 摘要

79. National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. Mar 2014 [internet publication].全文

80. Bola J, Kao D, Soydan H. Antipsychotic medication for early episode schizophrenia. Cochrane Database Syst Rev. 2011 Jun 15;(6):CD006374.全文  摘要

81. Samara MT, Leucht C, Leeflang MM, et al. Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am J Psychiatry. 2015 Jul;172(7):617-29. 摘要

82. Samara MT, Klupp E, Helfer B, et al. Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia. Cochrane Database Syst Rev. 2018 May 11;(5):CD011884.全文  摘要

83. Kreyenbuhl J, Buchanan RW, Dickerson FB, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010 Jan;36(1):94-103.全文  摘要

84. Zhu Y, Krause M, Huhn M, et al. Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry. 2017 Sep;4(9):694-705. 摘要

85. Hui CL, Honer WG, Lee EH, et al. Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial. Lancet Psychiatry. 2018 May;5(5):432-42. 摘要

86. Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012 Jul;13(5):318-78.全文  摘要

87. Leucht S, Tardy M, Komossa K, et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2012 May 16;(5):CD008016.全文  摘要

88. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012 Jun 2;379(9831):2063-71. 摘要

89. Dudley K, Liu X, De Haan S. Chlorpromazine dose for people with schizophrenia. Cochrane Database Syst Rev. 2017 Apr 13;(4):CD007778.全文  摘要

90. Correll CU, Yu X, Xiang Y, et al. Biological treatment of acute agitation or aggression with schizophrenia or bipolar disorder in the inpatient setting. Ann Clin Psychiatry. 2017 May;29(2):92-107. 摘要

91. Ostinelli EG, Jajawi S, Spyridi S, et al. Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev. 2018 Jan 8;(1):CD008074.全文  摘要

92. Howes OD, McCutcheon R, Agid O, et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017 Mar 1;174(3):216-29.全文  摘要

93. Stroup TS, Gerhard T, Crystal S, et al. Comparative effectiveness of adjunctive psychotropic medications in patients with schizophrenia. JAMA Psychiatry. 2019 May 1;76(5):508-15. 摘要

94. Correll CU, Rubio JM, Inczedy-Farkas G, et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry. 2017 Jul 1;74(7):675-84.全文  摘要

95. Siskind D, McCartney L, Goldschlager R, et al. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016 Nov;209(5):385-92. 摘要

96. Siskind D, Siskind V, Kisely S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. Can J Psychiatry. 2017 Nov;62(11):772-77.全文  摘要

97. Tiihonen J, Taipale H, Mehtälä J, et al. Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry. 2019 May 1;76(5):499-507.全文  摘要

98. Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia - a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011 Apr;127(1-3):83-92. 摘要

99. Koola MM, Wehring HJ, Kelly DL. The potential role of long-acting injectable antipsychotics in people with schizophrenia and comorbid substance use. J Dual Diagn. 2012;8(1):50-61.全文  摘要

100. Kishimoto T, Nitta M, Borenstein M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013 Oct;74(10):957-65. 摘要

101. Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry. 2017 Jul 1;74(7):686-93. 摘要

102. Zheng W, Xiang YT, Yang XH, et al. Clozapine augmentation with antiepileptic drugs for treatment-resistant schizophrenia: a meta-analysis of randomized controlled trials. J Clin Psychiatry. 2017 May;78(5):e498-505. 摘要

103. Pae CU, Wang SM, Han C, et al. Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison. Int Clin Psychopharmacol. 2017 Sep;32(5):235-48. 摘要

104. Belgamwar RB, El-Sayeh HG. Aripiprazole vs placebo for schizophrenia. Schizophr Bull. 2012 May;38(3):382-3.全文  摘要

105. Belgamwar RB, El-Sayeh HG. Aripiprazole versus placebo for schizophrenia. Cochrane Database Syst Rev. 2011 Aug 10;(8):CD006622.全文  摘要

106. Khanna P, Suo T, Komossa K, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2014 Jan 2;(1):CD006569.全文  摘要

107. Bellantuono C, Santone G. Efficacy, tolerability and safety of paliperidone extended-release in the treatment of schizophrenia and schizoaffective disorder [in Italian]. Riv Psichiatr. 2012 Jan-Feb;47(1):5-20. 摘要

108. Singh J, Robb A, Vijapurkar U, et al. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biol Psychiatry. 2011 Dec 15;70(12):1179-87. 摘要

109. Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database Syst Rev. 2004;(2):CD000967.全文  摘要

110. Sparshatt A, Taylor D, Patel MX, et al. Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review. J Clin Psychiatry. 2011 Aug;72(8):1108-23. 摘要

111. Li C, Xia J, Wang J. Risperidone dose for schizophrenia. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007474.全文  摘要

112. Bagnall A, Lewis RA, Leitner ML, et al. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database Syst Rev. 2000;(4):CD001945.全文  摘要

113. Hay A, Byers A, Sereno M, et al. Asenapine versus placebo for schizophrenia. Cochrane Database Syst Rev. 2015 Nov 24;(11):CD011458.全文  摘要

114. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. 2011 Feb;65(2):189-210.全文  摘要

115. Citrome L, Cucchiaro J, Sarma K, et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol. 2012 May;27(3):165-76. 摘要

116. European Medicines Agency. Questions and answers: refusal of the marketing authorisation for Fanaptum (iloperidone). Nov 2017 [internet publication].全文

117. Correll CU, Skuban A, Ouyang J, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015 Sep 1;172(9):870-80. 摘要

118. Marder SR, Hakala MJ, Josiassen MK, et al. Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies. Acta Neuropsychiatr. 2017 Oct;29(5):278-90. 摘要

119. Durgam S, Starace A, Li D, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014 Feb;152(2-3):450-7.全文  摘要

120. Nielsen J, Damkier P, Lublin H, et al. Optimizing clozapine treatment. Acta Psychiatr Scand. 2011 Jun;123(6):411-22. 摘要

121. Nussbaum A, Stroup TS. Oral paliperidone for schizophrenia. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006369.全文  摘要

122. Nussbaum AM, Stroup TS. Paliperidone palmitate for schizophrenia. Cochrane Database Syst Rev. 2012 Jun 13;(6):CD008296.全文  摘要

123. Coppola DM, Melkote R, Lannie C, et al. Efficacy and safety of paliperidone extended release 1.5 mg/day - a double-blind, placebo- and active-controlled, study in the treatment of patients with schizophrenia. Psychopharmacol Bull. 2011 May 15;44(2):54-72.全文  摘要

124. Citrome L. Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Int J Clin Pract. 2010 Jan;64(2):216-39. 摘要

125. Maayan N, Quraishi SN, David A, et al. Fluphenazine decanoate (depot) and enanthate for schizophrenia. Cochrane Database Syst Rev. 2015 Feb 5;(2):CD000307.全文  摘要

126. Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011 Mar 3;364(9):842-51.全文  摘要

127. Newton R, Hustig H, Lakshmana R, et al. Practical guidelines on the use of paliperidone palmitate in schizophrenia. Curr Med Res Opin. 2012 Apr;28(4):559-67. 摘要

128. Ascher-Svanum H, Zhao F, Detke HC, et al. Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia. BMC Psychiatry. 2011 Sep 23;11:152.全文  摘要

129. Witte MM, Case MG, Schuh KJ, et al. Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia. Curr Med Res Opin. 2012 Mar;28(3):315-23. 摘要

130. Fagiolini A, De Filippis S, Azzarelli O, et al. Intramuscular aripiprazole for the treatment of agitation in schizophrenia and bipolar disorder: from clinical research to clinical practice. J Psychopath. 2013 Mar;19(1):34-41.全文

131. Peuskens J. Good medical practice in antipsychotic pharmacotherapy. Int Clin Psychopharmacol. 1998 Mar;13 suppl 3:S35-41. 摘要

132. Schneider-Thoma J, Efthimiou O, Huhn M, et al. Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials. Lancet Psychiatry. 2018 Aug;5(8):653-63. 摘要

133. Kishimoto T, Agarwal V, Kishi T, et al. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry. 2013 Jan;18(1):53-66.全文  摘要

134. Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006654.全文  摘要

135. Zhang Y, Liu Y, Su Y, et al. The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. BMC Psychiatry. 2017 Nov 21;17(1):373.全文  摘要

136. Corponi F, Serretti A, Montgomery S, et al. Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials. Int Clin Psychopharmacol. 2017 Nov;32(6):309-18. 摘要

137. Buchanan RW, Panagides J, Zhao J, et al. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol. 2012 Feb;32(1):36-45. 摘要

138. Stephenson CM, Pilowsky LS. Psychopharmacology of olanzapine: a review. Br J Psychiatry Suppl. 1999;(38):52-8. 摘要

139. Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med. 2009 Oct;39(10):1591-602. 摘要

140. Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs. 2009 Aug;23(8):649-59. 摘要

141. Sussman N. Choosing an atypical antipsychotic. Int Clin Psychopharmacol. 2002 Aug;17 suppl 3:S29-33. 摘要

142. Zhang Y, Dai G. Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China. Hum Psychopharmacol. 2012 Nov;27(6):605-14. 摘要

143. Pajonk FG. Risperidone in acute and long-term therapy of schizophrenia - a clinical profile. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jan;28(1):15-23. 摘要

144. Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract. 2007 Jan;13(1):13-24. 摘要

145. Komossa K, Rummel-Kluge C, Schwarz S, et al. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD006626.全文  摘要

146. Daumit GL, Goff DC, Meyer JM, et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res. 2008 Oct;105(1-3):175-87.全文  摘要

147. Citrome L. Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm. J Clin Psychopharmacol. 2017 Apr;37(2):138-47. 摘要

148. Naber D, Lambert M. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Dec;28(8):1213-9. 摘要

149. Doey T. Aripiprazole in pediatric psychosis and bipolar disorder: a clinical review. J Affect Disord. 2012;138 suppl:S15-21. 摘要

150. Fusar-Poli P, Kempton MJ, Rosenheck RA. Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin Psychopharmacol. 2013 Mar;28(2):57-66. 摘要

151. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005 Sep 22;353(12):1209-23.全文  摘要

152. Gentile S. Antipsychotic therapy during early and late pregnancy: a systematic review. Schizophr Bull. 2010 May;36(3):518-44.全文  摘要

153. Rummel C, Kissling W, Leucht S. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD005581.全文  摘要

154. Singh SP, Singh V, Kar N, et al. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry. 2010 Sep;197(3):174-9. 摘要

155. Phan SV, Kreys TJ. Adjunct mirtazapine for negative symptoms of schizophrenia. Pharmacotherapy. 2011 Oct;31(10):1017-30. 摘要

156. Helfer B, Samara MT, Huhn M, et al. Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry. 2016 Sep 1;173(9):876-86. 摘要

157. Matthews PR, Horder J, Pearce M. Selective noradrenaline reuptake inhibitors for schizophrenia. Cochrane Database Syst Rev. 2018 Jan 25;(1):CD010219.全文  摘要

158. Singh J, Kour K, Jayaram MB. Acetylcholinesterase inhibitors for schizophrenia. Cochrane Database Syst Rev. 2012 Jan 18;(1):CD007967.全文  摘要

159. Rezaei F, Mohammad-Karimi M, Seddighi S, et al. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2013 Jun;33(3):336-42. 摘要

160. Kishi T, Matsuda Y, Iwata N. Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis. Psychopharmacology (Berl). 2017 Jul;234(14):2113-25. 摘要

161. Bennett AC, Vila TM. The role of ondansetron in the treatment of schizophrenia. Ann Pharmacother. 2010 Jul-Aug;44(7-8):1301-6. 摘要

162. Levkovitz Y, Menlovich S, Riwkes S, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010 Feb;71(2):138-49. 摘要

163. Liu F, Guo X, Wu R, et al. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. Schizophr Res. 2014 Mar;153(1-3):169-76. 摘要

164. Xiang YQ, Zheng W, Wang SB, et al. Adjunctive minocycline for schizophrenia: a meta-analysis of randomized controlled trials. Eur Neuropsychopharmacol. 2017 Jan;27(1):8-18. 摘要

165. Singh V, Singh SP, Chan K. Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia. Int J Neuropsychopharmacol. 2010 Mar;13(2):257-71. 摘要

166. Zullino D, Delacrausaz P, Baumann P. The place of SSRIs in the treatment of schizophrenia [in French]. Encephale. 2002 Sep-Oct;28(5 Pt 1):433-8. 摘要

167. Gregory A, Mallikarjun P, Upthegrove R. Treatment of depression in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2017 Oct;211(4):198-204. 摘要

168. van Dijk HG, Dapper EA, Vinkers CH. SSRIs and depressive symptoms in schizophrenia: a systematic review [in Dutch]. Tijdschr Psychiatr. 2017;59(1):40-6. 摘要

169. Chakos MH, Glick ID, Miller AL, et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv. 2006 Aug;57(8):1094-101. 摘要

170. Read J, Bentall R. The effectiveness of electroconvulsive therapy: a literature review. Epidemiol Psichiatr Soc. 2010 Oct-Dec;19(4):333-47. 摘要

171. Sinclair DJ, Zhao S, Qi F, et al. Electroconvulsive therapy for treatment-resistant schizophrenia. Cochrane Database Syst Rev. 2019 Mar 19;(3):CD011847.全文  摘要

172. Petrides G, Malur C, Braga RJ, et al. Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry. 2015 Jan;172(1):52-8. 摘要

173. Asher L, Patel V, De Silva MJ. Community-based psychosocial interventions for people with schizophrenia in low and middle-income countries: systematic review and meta-analysis. BMC Psychiatry. 2017 Oct 30;17(1):355.全文  摘要

174. Chang WC, Chan GH, Jim OT, et al. Optimal duration of an early intervention programme for first-episode psychosis: randomised controlled trial. Br J Psychiatry. 2015 Jun;206(6):492-500. 摘要

175. Dieterich M, Irving CB, Bergman H, et al. Intensive case management for severe mental illness. Cochrane Database Syst Rev. 2017 Jan 6;(1):CD007906.全文  摘要

176. Zhao S, Sampson S, Xia J, et al. Psychoeducation (brief) for people with serious mental illness. Cochrane Database Syst Rev. 2015 Apr 9;(4):CD010823.全文  摘要

177. Almerie MQ, Okba Al Marhi M, Jawoosh M, et al. Social skills programmes for schizophrenia. Cochrane Database Syst Rev. 2015 Jun 9;(6):CD009006.全文  摘要

178. Carmona VR, Gómez-Benito J, Huedo-Medina TB, et al. Employment outcomes for people with schizophrenia spectrum disorder: a meta-analysis of randomized controlled trials. Int J Occup Med Environ Health. 2017 May 8;30(3):345-66.全文  摘要

179. Hoffmann H, Jäckel D, Glauser S, et al. Long-term effectiveness of supported employment: 5-year follow-up of a randomized controlled trial. Am J Psychiatry. 2014 Nov 1;171(11):1183-90.全文  摘要

180. Suijkerbuijk YB, Schaafsma FG, van Mechelen JC, et al. Interventions for obtaining and maintaining employment in adults with severe mental illness, a network meta-analysis. Cochrane Database Syst Rev. 2017 Sep 12;(9):CD011867.全文  摘要

181. Drake RE, Frey W, Bond GR, et al. Assisting Social Security Disability Insurance beneficiaries with schizophrenia, bipolar disorder, or major depression in returning to work. Am J Psychiatry. 2013 Dec;170(12):1433-41. 摘要

182. Lynch D, Laws KR, McKenna PJ. Cognitive behavioural therapy for major psychiatric disorder: does it really work? A meta-analytical review of well-controlled trials. Psychol Med. 2010 Jan;40(1):9-24. 摘要

183. Jones C, Hacker D, Meaden A, et al. Cognitive behavioural therapy plus standard care versus standard care plus other psychosocial treatments for people with schizophrenia. Cochrane Database Syst Rev. 2018 Nov 15;(11):CD008712.全文  摘要

184. Jones C, Hacker D, Xia J, et al. Cognitive behavioural therapy plus standard care versus standard care for people with schizophrenia. Cochrane Database Syst Rev. 2018 Dec 20;(12):CD007964.全文  摘要

185. Kennedy L, Xyrichis A. Cognitive behavioral therapy compared with non-specialized therapy for alleviating the effect of auditory hallucinations in people with reoccurring schizophrenia: a systematic review and meta-analysis. Community Ment Health J. 2017 Feb;53(2):127-33. 摘要

186. McGurk SR, Mueser KT, Xie H, et al. Cognitive enhancement treatment for people with mental illness who do not respond to supported employment: a randomized controlled trial. Am J Psychiatry. 2015 Sep 1;172(9):852-61. 摘要

187. Kluwe-Schiavon B, Sanvicente-Vieira B, Kristensen CH, et al. Executive functions rehabilitation for schizophrenia: a critical systematic review. J Psychiatr Res. 2013 Jan;47(1):91-104. 摘要

188. Turner DT, van der Gaag M, Karyotaki E, et al. Psychological interventions for psychosis: a meta-analysis of comparative outcome studies. Am J Psychiatry. 2014 May;171(5):523-38. 摘要

189. Jauhar S, McKenna PJ, Radua J, et al. Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. Br J Psychiatry. 2014 Jan;204(1):20-9. 摘要

190. Cella M, Preti A, Edwards C, et al. Cognitive remediation for negative symptoms of schizophrenia: a network meta-analysis. Clin Psychol Rev. 2017 Mar;52:43-51.全文  摘要

191. Darmedru C, Demily C, Franck N. Cognitive remediation and social cognitive training for violence in schizophrenia: a systematic review. Psychiatry Res. 2017 May;251:266-74. 摘要

192. Pharoah F, Mari J, Rathbone J, et al. Family intervention for schizophrenia. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD000088.全文  摘要

193. Xia J, Merinder LB, Belgamwar MR. Psychoeducation for schizophrenia. Cochrane Database Syst Rev. 2011 Jun 15;(6):CD002831.全文  摘要

194. Katschnig H. Rehabilitation in schizophrenia - guidelines for including psychosocial measures [in German]. Wien Med Wochenschr. 1998;148(11-12):273-80. 摘要

195. Matsui M, Arai H, Yonezawa M, et al. The effects of cognitive rehabilitation on social knowledge in patients with schizophrenia. Appl Neuropsychol. 2009 Jul;16(3):158-64. 摘要

196. Guo X, Zhai J, Liu Z, et al. Effect of antipsychotic medication alone vs combined with psychosocial intervention on outcomes of early-stage schizophrenia: a randomized, 1-year study. Arch Gen Psychiatry. 2010 Sep;67(9):895-904.全文  摘要

197. Barrowclough C, Haddock G, Wykes T, et al. Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: randomised controlled trial. BMJ. 2010 Nov 24;341:c6325.全文  摘要

198. Malmberg L, Fenton M. Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness. Cochrane Database Syst Rev. 2001;(3):CD001360.全文  摘要

199. Canadian Agency for Drugs and Technologies in Health. Group therapy in the treatment of schizophrenia: a review of the clinical effectiveness. Nov 2009 [internet publication].全文

200. Vancampfort D, Probst M, Helvik Skjaerven L, et al. Systematic review of the benefits of physical therapy within a multidisciplinary care approach for people with schizophrenia. Phys Ther. 2012 Jan;92(1):11-23. 摘要

201. Vancampfort D, Knapen J, Probst M, et al. A systematic review of correlates of physical activity in patients with schizophrenia. Acta Psychiatr Scand. 2012 May;125(5):352-62. 摘要

202. Firth J, Cotter J, Carney R, et al. The pro-cognitive mechanisms of physical exercise in people with schizophrenia. Br J Pharmacol. 2017 Oct;174(19):3161-72.全文  摘要

203. Firth J, Stubbs B, Rosenbaum S, et al. Aerobic exercise improves cognitive functioning in people with schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2017 May 1;43(3):546-56.全文  摘要

204. Cabral P, Meyer HB, Ames D. Effectiveness of yoga therapy as a complementary treatment for major psychiatric disorders: a meta-analysis. Prim Care Companion CNS Disord. 2011;13(4):PCC.0r01068.全文  摘要

205. Vancampfort D, Vansteelandt K, Scheewe T, et al. Yoga in schizophrenia: a systematic review of randomised controlled trials. Acta Psychiatr Scand. 2012 Jul;126(1):12-20. 摘要

206. Broderick J, Knowles A, Chadwick J, et al. Yoga versus standard care for schizophrenia. Cochrane Database Syst Rev. 2015 Oct 21;(10):CD010554.全文  摘要

207. Broderick J, Vancampfort D. Yoga as part of a package of care versus standard care for schizophrenia. Cochrane Database Syst Rev. 2017 Sep 29;(9):CD012145.全文  摘要

208. Geretsegger M, Mössler KA, Bieleninik Ł, et al. Music therapy for people with schizophrenia and schizophrenia-like disorders. Cochrane Database Syst Rev. 2017 May 29;(5):CD004025.全文  摘要

209. Lee TY, Chang SC, Chu H, et al. The effects of assertiveness training in patients with schizophrenia: a randomized, single-blind, controlled study. J Adv Nurs. 2013 Nov;69(11):2549-59. 摘要

210. Zhuo C, Triplett PT. Association of schizophrenia with the risk of breast cancer incidence: a meta-analysis. JAMA Psychiatry. 2018 Apr 1;75(4):363-9.全文  摘要

211. Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry. 1988 Nov;39(11):1172-7. 摘要

212. Bora E, Akdede BB, Alptekin K. The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis. Psychol Med. 2017 Apr;47(6):1030-40. 摘要

213. Pillinger T, Beck K, Gobjila C, et al. Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis. JAMA Psychiatry. 2017 Mar 1;74(3):261-9. 摘要

214. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004 Feb;65(2):267-72. 摘要

215. Daumit GL, Dickerson FB, Wang NY, et al. A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med. 2013 Apr 25;368(17):1594-602.全文  摘要

216. Bartels SJ, Pratt SI, Aschbrenner KA, et al. Pragmatic replication trial of health promotion coaching for obesity in serious mental illness and maintenance of outcomes. Am J Psychiatry. 2015 Apr;172(4):344-52.全文  摘要

217. Halbreich U, Kahn LS. Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects. J Psychiatr Pract. 2003 Sep;9(5):344-53. 摘要

218. Royal Pharmaceutical Society; British Medical Association. British national formulary. London: BNF Publications; 2019.全文

219. Ayerbe L, Forgnone I, Addo J, et al. Hypertension risk and clinical care in patients with bipolar disorder or schizophrenia; a systematic review and meta-analysis. J Affect Disord. 2018 Jan 1;225:665-70. 摘要

220. Bauer-Staeb C, Jörgensen L, Lewis G, et al. Prevalence and risk factors for HIV, hepatitis B, and hepatitis C in people with severe mental illness: a total population study of Sweden. Lancet Psychiatry. 2017 Sep;4(9):685-93.全文  摘要

221. González-Rodríguez A, Seeman MV. Pharmacotherapy for schizophrenia in postmenopausal women. Expert Opin Pharmacother. 2018 Jun;19(8):809-21. 摘要

222. Brzezinski A, Brzezinski-Sinai NA, Seeman MV. Treating schizophrenia during menopause. Menopause. 2017 May;24(5):582-8. 摘要

223. Conley RR, Kelly DL. Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects. Isr J Psychiatry Relat Sci. 2005;42(1):51-60. 摘要

224. Tandon R, Fleischhacker WW. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res. 2005 Nov 15;79(2-3):145-55. 摘要

225. VanderZwaag C, McGee M, McEvoy JP, et al. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry. 1996 Dec;153(12):1579-84. 摘要

226. Remington G, Chong SA. Conventional versus novel antipsychotics: changing concepts and clinical implications. J Psychiatry Neurosci. 1999 Nov;24(5):431-41.全文  摘要

227. Haddad PM, Taylor M, Niaz OS. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. Br J Psychiatry Suppl. 2009 Nov;52:S20-8. 摘要

228. European Medicines Agency. New measures to avoid valproate exposure in pregnancy endorsed. Mar 2018 [internet publication].全文

229. Zaman H, Sampson SJ, Beck AL, et al. Benzodiazepines for psychosis-induced aggression or agitation. Cochrane Database Syst Rev. 2017 Dec 8;(12):CD003079.全文  摘要

230. Centorrino F, Baldessarini RJ, Frankenburg FR, et al. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry. 1996 Jun;153(6):820-2. 摘要

231. Zheng W, Cai DB, Yang XH, et al. Adjunctive celecoxib for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials. J Psychiatr Res. 2017 Sep;92:139-46. 摘要

232. Sommer IE, de Witte L, Begemann M, et al. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry. 2012 Apr;73(4):414-9. 摘要

233. Kishi T, Matsuda Y, Nakamura H, et al. Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials. J Psychiatr Res. 2013 Feb;47(2):149-54. 摘要

234. Lane HY, Lin CH, Green MF, et al. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry. 2013 Dec;70(12):1267-75. 摘要

235. Kulkarni J, Gavrilidis E, Gwini SM, et al. Effect of adjunctive raloxifene therapy on severity of refractory schizophrenia in women: a randomized clinical trial. JAMA Psychiatry. 2016 Sep 1;73(9):947-54. 摘要

236. Yu H, Yan H, Wang L, et al; Chinese Antipsychotics Pharmacogenomics Consortium. Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study. Lancet Psychiatry. 2018 Apr;5(4):327-38. 摘要

237. Essali A, Al-Haj Haasan N, Li C, et al. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD000059.全文  摘要

238. Ananth J, Parameswaran S, Hara B. Drug therapy in schizophrenia. Curr Pharm Des. 2004;10(18):2205-17. 摘要

239. Kern RS, Glynn SM, Horan WP, et al. Psychosocial treatments to promote functional recovery in schizophrenia. Schizophr Bull. 2009 Mar;35(2):347-61.全文  摘要

240. Horan WP, Kern RS, Shokat-Fadai K, et al. Social cognitive skills training in schizophrenia: an initial efficacy study of stabilized outpatients. Schizophr Res. 2009 Jan;107(1):47-54.全文  摘要

241. Kane JM, McGlashan TH. Treatment of schizophrenia. Lancet. 1995 Sep 23;346(8978):820-5. 摘要

242. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991;17(2):325-51. 摘要

243. Larsen TK, McGlashan TH, Moe LC. First-episode schizophrenia: I. Early course parameters. Schizophr Bull. 1996;22(2):241-56. 摘要

244. Malla AK, Norman RM, Manchanda R, et al. Status of patients with first-episode psychosis after one year of phase-specific community-oriented treatment. Psychiatr Serv. 2002 Apr;53(4):458-63. 摘要

245. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999 Apr;156(4):544-9. 摘要

246. Coyle JT. Substance use disorders and schizophrenia: a question of shared glutamatergic mechanisms. Neurotox Res. 2006 Dec;10(3-4):221-33. 摘要

247. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2013 Feb 28;(2):CD007253.全文  摘要

248. Barnes TR, Soares-Weiser K, Bacaltchuk J, et al. Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD001946.全文  摘要

249. Cubo E, Gracies JM, Benabou R, et al. Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Arch Neurol. 2001 Sep;58(9):1379-82.全文  摘要

250. Glassman AH. Schizophrenia, antipsychotic drugs, and cardiovascular disease. J Clin Psychiatry. 2005;66 suppl 6:5-10. 摘要

251. Gray R, Gournay K. What can we do about acute extrapyramidal symptoms? J Psychiatr Ment Health Nurs. 2000 Jun;7(3):205-11. 摘要

252. Velamoor VR, Swamy GN, Parmar RS, et al. Management of suspected neuroleptic malignant syndrome. Can J Psychiatry. 1995 Nov;40(9):545-50. 摘要

253. Klemp M, Tvete IF, Skomedal T, et al. A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo. J Clin Psychopharmacol. 2011 Dec;31(6):698-704. 摘要

254. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology. 2003 Jan;28 suppl 1:83-96. 摘要

255. Das C, Mendez G, Jagasia S, et al. Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments. Ann Clin Psychiatry. 2012 Aug;24(3):225-39. 摘要

256. Mahmood S, Booker I, Huang J, et al. Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents. J Clin Psychopharmacol. 2013 Feb;33(1):90-4. 摘要

257. Mukundan A, Faulkner G, Cohn T, et al. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.Cochrane Database Syst Rev. 2010 Dec 8;(12):CD006629.全文  摘要

258. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res. 2004 Dec 1;71(2-3):195-212. 摘要

259. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007;68 suppl 1:20-27. 摘要

260. Nunes LV, Moreira HC, Razzouk D, et al. Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review. J Sex Marital Ther. 2012;38(3):281-301. 摘要

261. Bacconi L, Gressier F. Efficacy and tolerance of PDE-5 in the treatment of erectile dysfunction in schizophrenic patients: a literature review [in French]. Encephale. 2017 Feb;43(1):55-61. 摘要

262. Glassman AH, Bigger JT, Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001 Nov;158(11):1774-82.全文  摘要

263. Collaborative Working Group on Clinical Trial Evaluations. Adverse effects of the atypical antipsychotics. J Clin Psychiatry. 1998;59 suppl 12:17-22. 摘要

264. Farooq S, Johal RK, Ziff C, et al. Different communication strategies for disclosing a diagnosis of schizophrenia and related disorders. Cochrane Database Syst Rev. 2017 Oct 24;(10):CD011707.全文  摘要

265. Medicines and Healthcare products Regulatory Agency. Valproate medicines (Epilim, Depakote): Pregnancy Prevention Programme materials online. May 2018 [internet publication].全文